Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting
October 03, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
New lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presentedSystemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU...
Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
June 12, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
ACR CRISS score remains ≥ 0.95 (95%) at 21 months in systemic sclerosis open-label extension (OLE) studyCDASI activity score reaches -21.8 points at 16 months in dermatomyositis OLE study81% systemic...
Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting
May 28, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
New data from ongoing Phase 2 open-label extension of lenabasum in systemic sclerosis and open-label extension data in dermatomyositis studies to be presentedPresentation includes data from some...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bridgepoint, Corbus, and NIO and Encourages Investors to Contact the Firm
May 08, 2019 22:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Bridgepoint Education, Inc.,...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Inogen, Spectrum Brands, Bridgepoint, and Corbus and Encourages Investors to Contact the Firm
May 02, 2019 22:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Inogen, Inc., Spectrum Brands...
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019
May 01, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 01, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Inogen, Spectrum Brands, Bridgepoint, and Corbus and Encourages Investors to Contact the Firm
April 25, 2019 22:20 ET
|
Bragar Eagel & Squire
NEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Inogen, Inc., Spectrum...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Inogen, Spectrum Brands, Bridgepoint, and Corbus and Encourages Investors to Contact the Firm
April 12, 2019 06:39 ET
|
Bragar Eagel & Squire
NEW YORK, April 12, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Inogen, Inc., Spectrum...
Corbus Pharmaceuticals Appoints Rachelle Jacques to Board of Directors
April 08, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Appointment brings global commercialization and marketing experience for rare diseases to the Board of Directors Appointment aligns with Company’s vision to become the leader in the treatment of...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Inogen, Spectrum Brands, Bridgepoint, and Corbus and Encourages Investors to Contact the Firm
April 04, 2019 06:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Inogen, Inc., Spectrum...